

# Anja Lorch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3363851/publications.pdf>

Version: 2024-02-01

53  
papers

3,401  
citations

304602

22  
h-index

182361

51  
g-index

64  
all docs

64  
docs citations

64  
times ranked

2811  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	0.9	158
2	Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. <i>British Journal of Cancer</i> , 2022, 126, 1140-1144.	2.9	23
3	Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome. <i>World Journal of Urology</i> , 2021, 39, 2579-2585.	1.2	2
4	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	0.9	1,152
5	Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2671-2679.	1.2	7
6	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021, 39, 3407-3414.	1.2	4
7	Renal cell carcinoma pathology in 2021: a new need for renal cancer immune profiling™. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	0.9	5
8	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	0.8	83
9	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	0.8	108
10	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	2.6	61
11	Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 449-455.	1.2	10
12	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
13	Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1322-1331.	0.8	23
14	Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2829-2841.	1.2	23
15	Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	1.3	8
16	European Association of Urology Guidelines on Primary Urethral Carcinoma – 2020 Update. <i>European Urology Oncology</i> , 2020, 3, 424-432.	2.6	28
17	Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. <i>Oncologist</i> , 2020, 25, 585-590.	1.9	22
18	Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer. <i>Cancers</i> , 2020, 12, 749.	1.7	44

#	ARTICLE	IF	CITATIONS
19	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 717-723.	1.2	25
20	Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 510-510.	0.8	1
21	Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting.. <i>Journal of Clinical Oncology</i> , 2019, 37, 524-524.	0.8	2
22	High $\beta$ -1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. <i>Oncolmmunology</i> , 2018, 7, e1423169.	2.1	10
23	Management of Refractory Germ Cell Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 324-329.	1.8	6
24	The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. <i>Oncology Research and Treatment</i> , 2018, 41, 365-369.	0.8	16
25	How we treat germ cell cancers. <i>Cancer</i> , 2017, 123, 2190-2192.	2.0	4
26	High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how. <i>World Journal of Urology</i> , 2017, 35, 1177-1184.	1.2	6
27	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 194-200.	0.8	41
28	Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care”Registry data from an outcomes research project of the German Testicular Cancer Study Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 168.e21-168.e28.	0.8	25
29	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options”An Analysis From the Global Germ Cell Cancer Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 345-351.	0.8	69
30	Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. <i>Annals of Oncology</i> , 2015, 26, 833-838.	0.6	57
31	First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 923-931.	1.2	7
32	How Should Patients with Recurrent Disease Be Treated Actually?. , 2015, , 73-79.		0
33	Sequential high-dose chemotherapy (HDCT) for relapsed or refractory germ cell cancer (rGCC): Results of a unicentric standardized approach.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15551-e15551.	0.8	0
34	Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15570-e15570.	0.8	0
35	A practice-changing step forward in germ-cell cancer?. <i>Lancet Oncology, The</i> , 2014, 15, 1409-1410.	5.1	4
36	First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1211-20.	1.2	11

#	ARTICLE	IF	CITATIONS
37	A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT).. Journal of Clinical Oncology, 2014, 32, e15535-e15535.	0.8	1
38	Quality of life in patients undergoing paclitaxel-based second-line treatment of urothelial cancer.. Journal of Clinical Oncology, 2014, 32, e15508-e15508.	0.8	1
39	Bone metastases in germ cell tumors: Results from an international data base.. Journal of Clinical Oncology, 2014, 32, 4559-4559.	0.8	0
40	Prognostic impact of LDH levels in patients with relapsed/refractory seminoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1311-1316.	1.2	12
41	Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?. European Urology, 2013, 64, 355-357.	0.9	29
42	The Role of Residual Tumor Resection in the Management of Nonseminomatous Germ Cell Cancer of Testicular Origin. Thoracic and Cardiovascular Surgeon, 2012, 60, 405-412.	0.4	24
43	Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial. Journal of Clinical Oncology, 2012, 30, 800-805.	0.8	94
44	Addition of Darbeopetin Alfa to Sequential High Dose Vip Chemotherapy for Patients with Advanced Metastatic Germ Cell Cancer. Annals of Oncology, 2012, 23, ix284.	0.6	0
45	Late Relapse of Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2011, 25, 615-626.	0.9	7
46	Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Early Stage Seminomatous Testicular Germ Cell Cancer Patients. Strahlentherapie Und Onkologie, 2011, 187, 158-166.	1.0	22
47	Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Testicular Germ Cell Cancer Patients. Oncology Research and Treatment, 2011, 34, 59-64.	0.8	24
48	Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. Journal of Clinical Oncology, 2011, 29, 2178-2184.	0.8	226
49	High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Annals of Oncology, 2010, 21, 820-825.	0.6	68
50	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. Journal of Clinical Oncology, 2010, 28, 4906-4911.	0.8	267
51	Patterns of Relapse after Chemotherapy in Patients with High-Risk Non-Seminomatous Germ Cell Tumor. Oncology, 2010, 78, 47-53.	0.9	10
52	High Dose Chemotherapy as Salvage Treatment for Unresectable Late Relapse Germ Cell Tumors. Journal of Urology, 2010, 184, 168-173.	0.2	33
53	Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group. Journal of Clinical Oncology, 2007, 25, 2778-2784.	0.8	117